MX2012009074A - Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa. - Google Patents

Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa.

Info

Publication number
MX2012009074A
MX2012009074A MX2012009074A MX2012009074A MX2012009074A MX 2012009074 A MX2012009074 A MX 2012009074A MX 2012009074 A MX2012009074 A MX 2012009074A MX 2012009074 A MX2012009074 A MX 2012009074A MX 2012009074 A MX2012009074 A MX 2012009074A
Authority
MX
Mexico
Prior art keywords
pyrrolo
urea compounds
jak inhibitors
compounds
pyrimidine
Prior art date
Application number
MX2012009074A
Other languages
English (en)
Spanish (es)
Inventor
Timothy Allen Johnson
Ashley FENWICK
Graham M Kyne
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2012009074A publication Critical patent/MX2012009074A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2012009074A 2010-02-05 2011-01-24 Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa. MX2012009074A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30191510P 2010-02-05 2010-02-05
PCT/US2011/022216 WO2011097087A1 (en) 2010-02-05 2011-01-24 Pyrrolo [ 2, 3 - d] pyrimidine urea compounds as jak inhibitors

Publications (1)

Publication Number Publication Date
MX2012009074A true MX2012009074A (es) 2012-08-23

Family

ID=43629121

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012009074A MX2012009074A (es) 2010-02-05 2011-01-24 Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa.

Country Status (9)

Country Link
US (1) US20120309776A1 (enExample)
EP (1) EP2531508A1 (enExample)
JP (1) JP2013518882A (enExample)
CN (1) CN102822177A (enExample)
AU (1) AU2011213198B2 (enExample)
BR (1) BR112012019511A2 (enExample)
CA (1) CA2788071A1 (enExample)
MX (1) MX2012009074A (enExample)
WO (1) WO2011097087A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116187C2 (uk) 2005-12-13 2018-02-26 Інсайт Холдінгс Корпорейшн ГЕТЕРОАРИЛЗАМІЩЕНІ ПІРОЛО[2,3-b]ПІРИДИНИ Й ПІРОЛО[2,3-b]ПІРИМІДИНИ ЯК ІНГІБІТОРИ ЯНУС-КІНАЗИ
WO2014043257A1 (en) * 2012-09-12 2014-03-20 Rigel Pharmaceuticals, Inc. Treatment for vitiligo
NZ708157A (en) 2012-11-15 2019-07-26 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
CN103896946B (zh) * 2012-12-28 2018-04-03 浙江导明医药科技有限公司 用于预防及治疗多种自身免疫疾病的新化合物
WO2014118388A1 (en) 2013-02-04 2014-08-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for assaying jak2 activity in red blood cells and uses thereof
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
AU2014277506B2 (en) * 2013-06-07 2017-08-31 Jiangsu Hengrui Medicine Co., Ltd. Bisulfate of Janus kinase (JAK) inhibitor and preparation method therefor
HRP20200955T1 (hr) 2013-08-07 2020-10-02 Incyte Corporation Dozni oblici s produženim oslobađanjem za jak1 inhibitor
CN105732637B (zh) * 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
KR20180080330A (ko) 2015-11-24 2018-07-11 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 위장관 염증 질환의 치료를 위한 jak 저해제 화합물의 프로드러그
WO2017143014A1 (en) 2016-02-16 2017-08-24 Brian Kim Jak inhibitors and uses thereof
US10472366B2 (en) 2017-03-08 2019-11-12 Theravance Biopharma R&D Ip, Llc Glucuronide prodrugs of tofacitinib
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
US20200088732A1 (en) 2017-04-13 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Mèdicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
US10233174B2 (en) 2017-05-23 2019-03-19 Theravance Biopharma R&D Ip, Llc Thiocarbamate prodrugs of tofacitinib
US10745405B2 (en) 2017-05-23 2020-08-18 Theravance Biopharma R&D Ip, Llc Glucuronide prodrugs of Janus kinase inhibitors
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE247469T1 (de) * 1995-06-07 2003-09-15 Pfizer Heterocyclische kondensierte pyrimidin-derivate
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
EA005852B1 (ru) 1998-06-19 2005-06-30 Пфайзер Продактс Инк. ПИРРОЛО[2,3-d]ПИРИМИДИНЫ
SK287188B6 (sk) 1999-12-10 2010-02-08 Pfizer Products Inc. Pyrolo [2,3-d]pyrimidínová zlúčenina, jej použitie a farmaceutická kompozícia alebo kombinácia s jej obsahom
CN100351253C (zh) * 2000-06-26 2007-11-28 辉瑞产品公司 作为免疫抑制剂的吡咯并[2,3－d]嘧啶化合物
CN1217920C (zh) * 2000-06-30 2005-09-07 艾兰制药公司 治疗早老性痴呆的化合物
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
CN1726192A (zh) 2002-11-21 2006-01-25 辉瑞产品公司 3－氨基－哌啶衍生物及其制备方法
US7732237B2 (en) 2005-06-27 2010-06-08 The Regents Of The University Of California Quantum dot based optoelectronic device and method of making same
ES2377771T3 (es) * 2005-07-29 2012-03-30 Pfizer Products Inc. Derivados de pirrolo [2,3-d]pirimidina, sus intermedios y síntesis
WO2008029237A2 (en) * 2006-09-05 2008-03-13 Pfizer Products Inc. Combination therapies for rheumatoid arthritis

Also Published As

Publication number Publication date
JP2013518882A (ja) 2013-05-23
WO2011097087A1 (en) 2011-08-11
AU2011213198A1 (en) 2012-08-09
CN102822177A (zh) 2012-12-12
CA2788071A1 (en) 2011-08-11
AU2011213198B2 (en) 2014-04-24
EP2531508A1 (en) 2012-12-12
US20120309776A1 (en) 2012-12-06
BR112012019511A2 (pt) 2016-08-23

Similar Documents

Publication Publication Date Title
MX2012009074A (es) Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa.
IN2012DN02577A (enExample)
PH12015501779A1 (en) Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak)
UY32059A (es) Compuestos de pirrolo [2,3-d] pirimidina
PH12012502334A1 (en) Heteroaryl imidazolone derivatives as jak inhibitors
PH12016500938A1 (en) Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
MY156727A (en) N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
GEP201706620B (en) NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
HK1202541A1 (en) 2-amino, 6-phenyl substituted pyrido [2, 3 - d] pyrimidine derivatives useful as raf kinase inhibitors
MX2015010858A (es) Formas solidas de un inhbidor de cdk4/6 selectivo.
TW201713640A (en) Bruton's tyrosine kinase inhibitors
WO2012007345A3 (en) Substituted imidazo[1,2-a]pyrimidines and -pyridines
PH12014500103A1 (en) Pyridin-2(1h)-one derivatives as jak inhibitors
PH12012501164A1 (en) Imidazopyridine derivatives as jak inhibitors
WO2012054364A3 (en) Bicyclic diamines as janus kinase inhibitors
WO2013004995A8 (en) Pyrimidinone compounds and their use
JO2822B1 (en) Inhibitors of the enzyme kinase P70 S6 and AKT
LT2658844T (lt) Nauji pirimidino dariniai, jų gamyba ir jų farmacinis panaudojimas kaip akt (pkb) fosforilinimo slopiklių
CY1115106T1 (el) Ενωσεις πυρρολο[2,3-d]πυριμιδινης
TN2010000363A1 (en) Pyrrolo [2,3-d] pyridines and use thereof as tyrosine kinase inhibitors

Legal Events

Date Code Title Description
GB Transfer or rights
HC Change of company name or juridical status